{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:10:28Z","timestamp":1775167828333,"version":"3.50.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Identify the role of angiogenesis in non-small cell lung cancer (NSCLC). Explain the role of bevacizumab in apparently producing greater response, time to progression, and overall survival rates in a randomized phase II trial comparing carboplatin, paclitaxel, and bevacizumab with carboplatin and paclitaxel without bevacizumab and the limitations of this interpretation. Define the main toxicity concerns with the use of bevacizumab in the treatment of NSCLC.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit atCME.TheOncologist.com<\/jats:p>\n                  <jats:p>There is an urgent need for new therapies to treat non-small cell lung cancer (NSCLC), as progress with current chemotherapy regimens has been limited. The roles of vascular endothelial growth factor (VEGF) in promoting tumor angiogenesis, maintaining existing vasculature, and contributing to resistance to traditional therapies, together with its negative prognostic significance in NSCLC, make it an appropriate target for therapy. Bevacizumab (AvastinTM; Genentech Inc., South San Fransisco, CA), a monoclonal antibody directed against VEGF, has shown promise in treating a number of different cancers. In a recent phase II trial in patients with advanced metastatic NSCLC, the addition of bevacizumab to standard carboplatin\/paclitaxel chemotherapy produced a significantly longer time to progression (32.1 versus 18.4 weeks) and greater response rate (31% versus 19% [not significant]) than chemotherapy alone. In the subset of patients with nonsquamous histologies, response rates and survival were further enhanced, with a mean survival time of 17.9 months versus 12.3 months with chemotherapy alone.<\/jats:p>\n                  <jats:p>Bevacizumab was generally well tolerated and did not appear to increase the incidences or severities of the nausea\/vomiting, neuropathy, and renal toxicity that are typically associated with carboplatin\/paclitaxel chemotherapy. Adverse events in phase I and II studies included hypertension, thrombosis, proteinuria (with occasional nephrotic syndrome), and epistaxis. Serious tumor-related bleeding episodes (hemoptysis\/hematemesis) appear to be the main safety concern in patients with NSCLC, with squamous cell histology as a possible risk factor.<\/jats:p>\n                  <jats:p>Further work is needed to identify the best way to use bevacizumab in NSCLC, including use in combination with other biologic agents and in the adjuvant setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-suppl_1-19","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"19-26","source":"Crossref","is-referenced-by-count":54,"title":["Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?"],"prefix":"10.1093","volume":"9","author":[{"given":"Roy S.","family":"Herbst","sequence":"first","affiliation":[{"name":"M.D. Anderson Cancer Center, Department of Head and Neck Medical Oncology, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"Sandler","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Division of Hematology\/Oncology, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,6,1]]},"reference":[{"key":"2021122209454933800_R1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM200010263431710","article-title":"Non-small-cell lung cancer\u2014stalemate or progress?","volume":"343","author":"Carney","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122209454933800_R2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122209454933800_R3","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454933800_R4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"2021122209454933800_R5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy","volume":"9","author":"Ferrara","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209454933800_R6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1523-1755.1999.00610.x","article-title":"Role of vascular endothelial growth factor in the regulation of angiogenesis","volume":"56","author":"Ferrara","year":"1999","journal-title":"Kidney Int"},{"key":"2021122209454933800_R7","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","article-title":"VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells","volume":"18","author":"Asahara","year":"1999","journal-title":"EMBO J"},{"key":"2021122209454933800_R8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat Med"},{"key":"2021122209454933800_R9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/92.2.143","article-title":"Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models","volume":"92","author":"Li","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454933800_R10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi","year":"2001","journal-title":"Lancet Oncol"},{"key":"2021122209454933800_R11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/107327480200902S05","article-title":"Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers","volume":"9","author":"Rosen","year":"2002","journal-title":"Cancer Control"},{"key":"2021122209454933800_R12","first-page":"4373","article-title":"Prognostic role of angiogenesis in non-small cell lung cancer","volume":"21","author":"Giatromanolaki","year":"2001","journal-title":"Anticancer Res"},{"issue":"suppl 4","key":"2021122209454933800_R13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0169-5002(01)00386-5","article-title":"Angiogenesis and antiangiogenic agents in non-small cell lung cancer","volume":"34","author":"Galligioni","year":"2001","journal-title":"Lung Cancer"},{"key":"2021122209454933800_R14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.2001.19.2.432","article-title":"Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer","volume":"19","author":"Yuan","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454933800_R15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0169-5002(01)00246-X","article-title":"High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression","volume":"34","author":"Ushijima","year":"2001","journal-title":"Lung Cancer"},{"key":"2021122209454933800_R16","first-page":"3088","article-title":"Vascular endothelial growth factor\/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer","volume":"60","author":"Koukourakis","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209454933800_R17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.bjc.6600015","article-title":"Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas","volume":"86","author":"Passalidou","year":"2002","journal-title":"Br J Cancer"},{"key":"2021122209454933800_R18","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"2021122209454933800_R19","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209454933800_R20","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209454933800_R21","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"2021122209454933800_R22","first-page":"28b","article-title":"Toxicities of the antiangiogenic agent SU5416 in phase II studies","volume":"21","author":"Aklilu","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454933800_R23","first-page":"398","article-title":"A phase I dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787\/ZK222584 (PTK\/ZK) in patients with liver metastasis of advanced cancer","volume":"21","author":"Drevs","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454933800_R24","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"2021122209454933800_R25","volume-title":"Bevacizumab (Avastin\u2122) improves survival in metastatic colorectal cancer","author":"National Cancer Institute"},{"key":"2021122209454933800_R26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0147-0272(02)70005-6","article-title":"Angiogenesis and antiangiogenic therapy","volume":"26","author":"Sledge","year":"2002","journal-title":"Curr Probl Cancer"},{"key":"2021122209454933800_R27","article-title":"Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial","volume-title":"N Engl J Med","author":"Hurwitz","year":"2004"},{"key":"2021122209454933800_R28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122209454933800_R29","first-page":"32","article-title":"Successful long-term therapy with bevacizumab (Avastin\u2122) in solid tumors: preliminary report on extension study AVF0778g","volume":"21","author":"Langmuir","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"2021122209454933800_R30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.9-suppl_1-27","article-title":"Expanding the clinical development of bevacizumab","volume":"9","author":"Chen","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209454933800_R31","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209454933800_R32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/07357909809039771","article-title":"Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor","volume":"16","author":"Pham","year":"1998","journal-title":"Cancer Invest"},{"key":"2021122209454933800_R33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"2021122209454933800_R34","first-page":"488","article-title":"The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice","volume":"36","author":"Kabbinavar","year":"1995","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2021122209454933800_R35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jmri.10072","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme","volume":"15","author":"Gossmann","year":"2002","journal-title":"J Magn Reson Imaging"},{"key":"2021122209454933800_R36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0","article-title":"Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice","volume":"77","author":"Kanai","year":"1998","journal-title":"Int J Cancer"},{"key":"2021122209454933800_R37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.1998.tb00651.x","article-title":"Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm","volume":"89","author":"Konno","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"2021122209454933800_R38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-5347(01)61829-9","article-title":"Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model","volume":"161","author":"Melnyk","year":"1999","journal-title":"J Urol"},{"key":"2021122209454933800_R39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/bies.10043","article-title":"Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy","volume":"24","author":"Harmey","year":"2002","journal-title":"Bioessays"},{"key":"2021122209454933800_R40","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res"},{"key":"2021122209454933800_R41","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"2021122209454933800_R42","first-page":"2963","article-title":"Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function","volume":"5","author":"Gabrilovich","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122209454933800_R43","article-title":"A phase II, randomized trial comparing bevacizumab (Avastin\u2122) plus carboplatin\/paclitaxel with carboplatin\/paclitaxel alone in patients with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer","volume-title":"J Clin Oncol","author":"Johnson"},{"key":"2021122209454933800_R44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454933800_R45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","article-title":"Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data","volume":"19","author":"Margolin","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454933800_R46","first-page":"330a","article-title":"Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV)","volume":"20","author":"Novotny","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454933800_R47","volume-title":"Data on file"},{"key":"2021122209454933800_R48","first-page":"627","article-title":"Phase I\/II study of recombinant humanized monoclonal anti-VEGF antibody bevacizumab and EGFR-TK inhibitor erlotinib HCl in patients with recurrent non-small cell lung cancer (NSCLC)","volume":"22","author":"Mininberg","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454933800_R49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0093-7754(01)90047-8","article-title":"The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer","volume":"28","author":"Los","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454933800_R50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021122209454933800_R51","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.2910570624","article-title":"Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents","volume":"57","author":"Teicher","year":"1994","journal-title":"Int J Cancer"},{"key":"2021122209454933800_R52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"2021122209454933800_R53","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res"},{"key":"2021122209454933800_R54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI116165","article-title":"Expression of the vascular permeability factor\/vascular endothelial growth factor gene in central nervous system neoplasms","volume":"91","author":"Berkman","year":"1993","journal-title":"J Clin Invest"},{"key":"2021122209454933800_R55","first-page":"1569","article-title":"Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines","volume":"11","author":"Viglietto","year":"1995","journal-title":"Oncogene"},{"key":"2021122209454933800_R56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/bjc.1996.166","article-title":"Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma","volume":"73","author":"Mattern","year":"1996","journal-title":"Br J Cancer"},{"key":"2021122209454933800_R57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0046-8177(95)90119-1","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer","volume":"26","author":"Brown","year":"1995","journal-title":"Hum Pathol"},{"key":"2021122209454933800_R58","first-page":"4727","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract","volume":"53","author":"Brown","year":"1993","journal-title":"Cancer Res"},{"key":"2021122209454933800_R59","first-page":"1255","article-title":"Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas","volume":"143","author":"Brown","year":"1993","journal-title":"Am J Pathol"},{"key":"2021122209454933800_R60","first-page":"276","article-title":"Vascular permeability factor gene expression in normal and neoplastic human ovaries","volume":"54","author":"Olson","year":"1994","journal-title":"Cancer Res"},{"key":"2021122209454933800_R61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jnci\/87.16.1237","article-title":"Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia","volume":"87","author":"Guidi","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454933800_R62","first-page":"859","article-title":"Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma","volume":"73","author":"Hashimoto","year":"1995","journal-title":"Lab Invest"},{"key":"2021122209454933800_R63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr Rev"},{"key":"2021122209454933800_R64","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1349-7006.1994.tb02904.x","article-title":"Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer","volume":"85","author":"Toi","year":"1994","journal-title":"Jpn J Cancer Res"},{"key":"2021122209454933800_R65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jnci\/89.2.139","article-title":"Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma","volume":"89","author":"Gasparini","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454933800_R66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8","article-title":"p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma","volume":"89","author":"Linderholm","year":"2000","journal-title":"Int J Cancer"},{"key":"2021122209454933800_R67","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1200\/JCO.1998.16.9.3129","article-title":"Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients","volume":"16","author":"Eppenberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209454933800_R68","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2000.18.7.1423","article-title":"Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment","volume":"18","author":"Linderholm","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-suppl_1-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-suppl_1-19","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S1\/19\/41844451\/oncolo_9_s1_19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S1\/19\/41844451\/oncolo_9_s1_19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:24:06Z","timestamp":1640193846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/S1\/19\/6388098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":68,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2004,6,1]]},"published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-suppl_1-19","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,6,1]]},"published":{"date-parts":[[2004,6,1]]}}}